Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial

Andrew Radley,1 Marijn de Bruin,2 Sarah K Inglis,3 Peter T Donnan,3 John F Dillon4

ABSTRACT

Introduction Hepatitis C virus (HCV) infection affects 0.7% of the general population, and up to 40% of people prescribed opioid substitution therapy (OST) in Scotland. In conventional care, less than 10% of OST users are tested for HCV and less than 25% of those initiated treatment. Community pharmacists see this group frequently to provide OST supervision. This study examines whether a pharmacist-led ‘test & treat’ pathway increases cure rates for HCV.

Methods and analysis This protocol describes a cluster-randomised trial where 60 community pharmacies provide either conventional or pharmacy-led care. All pharmacies offer dried blood spot testing (DBST) for HCV. Participants have attended the pharmacy for OST for 3 months; are positive for HCV genotype 1 or 3; are not co-infected with HIV and/or hepatitis B; have no decompensated liver disease; are not pregnant. For conventional care, pharmacists refer HCV-positive participants to a local centre for assessment. In the pharmacy-led arm, pharmacists assess participants themselves in the pharmacy. Drug prescribing is by nurse prescribers (conventional arm) or pharmacist prescribers (pharmacy-led arm). Treatment in both arms is delivered as daily modified directly observed therapy in a pharmacy.

Primary trial outcome is number of sustained virological responses at 12 weeks after treatment completion. Secondary trials outcomes are number of tests taken; treatment uptake; completion; adherence; re-infection. An economic evaluation will assess potential cost-effectiveness. Qualitative research interviews with clients and health professionals will assess acceptability of a pharmacist-led pathway.

Ethics and dissemination This protocol has been ethically approved by the East of Scotland Research Ethics Committee 2 (15/ES/0086) and complies with the Declaration of Helsinki and principles of Good Clinical Practice. Caldicott guardian approval was given on 16 December 2016 to allow NHS Tayside to pass information to the cluster community pharmacies about the HCV test status of patients that they are seeing to provide OST supervision. NHS R&D approvals have been obtained from each health board taking part in the study. Informed consent is obtained before study enrolment and only anonymised data are stored in a secured database, enabling an audit trail. Results will be submitted to international peer-reviewed journals and presented at international conferences.

Trial registration number NCT02706223; Pre-results.

BACKGROUND

Hepatitis C is a bloodborne viral infection causing liver disease. Around 0.7% of the Scottish population are chronically infected with hepatitis C virus (HCV).1 Patient outcomes from HCV infection vary, with 25% clearing the infection spontaneously and the remainder becoming chronically infected, risking development of cirrhosis and hepatocellular carcinoma.2 A recent Public Health England report highlighted that less than half of those infected with HCV have been identified, and of those identified less than 3% of those known to be infected with HCV are being treated.3 The greatest risk of acquiring the virus in the UK is through injecting drug use1 and evidence suggests around 40% of
people in Scotland receiving opioid substitution therapy (OST) have HCV infection. Only a small proportion of this high-risk and vulnerable population are receiving adequate treatment, despite having daily healthcare interaction with a pharmacist and the availability of a curative intervention with widely available direct-acting antiviral (DAA) medication.

The conventional care pathway in the UK recommends that patients with a history of intravenous drug use, or those currently prescribed OST, should be offered HCV testing annually. Testing may be available from their GPs, drug workers, drug agencies, social workers, community pharmacies and needle exchanges. Once diagnosed, patients can be referred to established treatment pathways, usually based around hepatology teams in secondary care. In these established treatment pathways, less than 10% of the OST population is tested for HCV annually. Of those tested, at most 25% start treatment in one of the dedicated centres and 70%–80% successfully complete treatment, with treatment failure primarily caused by non-adherence and non-persistence to treatment. Similar patterns are observed in other countries. The inefficiency of established treatment pathways leads to increased preventable deaths from HCV and viral transmission within the injecting population.

A variety of reasons may explain the low rates of HCV testing, treatment uptake and treatment completion. People who inject drugs (PWID) may encounter a number of barriers that prevent them from accessing care, including perceptions and experience of stigma and discrimination, issues with the organisation of care, and the treatment policies of providers or payers. There are identified deficiencies in the extent of screening and diagnosis of at-risk populations, as well as the need to simplify pathways to enable treatment initiation and clinical monitoring. PWID may find it difficult to consistently attend medical clinics. WHO has set an ambitious goal to eliminate HCV as a public health threat by 2030.

Creating the complex interventions necessary to eradicate HCV requires that well-designed cross-disciplinary programmes are put in place using different strategies to increase screening, testing and diagnosis. Strategies that demonstrate increased testing and treatment uptake include the provision of integrated HCV care pathways with drug use and psychiatric services delivered by a multidisciplinary team and with case management services. The delivery of HCV testing and treatment through community-based care pathways has also been shown to be feasible and DBST has been demonstrated to increase the uptake of testing from high-risk populations. Hence, a more central role in the treatment of HCV for community-based pharmacists who are seeing these clients on a daily basis, could—in theory—lead to increased HCV treatment success rates through higher HCV testing, treatment uptake, adherence and treatment completion rates.

In preparation for the current trial investigating the clinical benefits of pharmacy-delivered HCV treatment, pilot work was undertaken guided by the Medical Research Council theoretical framework for developing and evaluating complex interventions. Initial work involved using a co-production approach in partnership with OST patients. This work identified the current experiences of patients in accessing HCV testing and treatment and in accessing OST in pharmacies. The attributes of an ideal service were identified and an estimate of potential uptake made. The implementation of DBST in pharmacies was undertaken and the experiences of patients and providers recorded. A pilot trial has been undertaken to test each stage of the pharmacy-led care pathway and to look for confirmation that an appropriately powered definitive multicentre randomised controlled trial would be feasible. The PRagmatic Explanatory Continuum Indictor Summary (PRECIS-2) tool was used to assess that the design decisions were concordant with the purpose of the trial (online supplementary file 1).

The aim of this research is to examine the impact of pharmacy-delivered HCV treatment on HCV treatment success rates among OST users. Our research questions are:

**Trial**

1. Does a community pharmacist-led HCV treatment pathway increase treatment success rates (sustained virological response, or SVR) compared with the conventional pathway?
2. Does a community pharmacist-led HCV treatment pathway lead to a higher uptake of HCV testing?
3. Does a community pharmacist-led HCV treatment pathway lead to a higher uptake and completion of HCV treatment?
4. Is adherence and persistence to HCV therapy in the pharmacy setting similar to that in the conventional pathway?
5. What is the re-infection rate at 12 months after end of treatment in all patients with SVR, and for the pharmacist-led pathway compared with the conventional pathway?

**Health economics study**

6. Is the pharmacist-led pathway potentially a cost-effective method of testing and treating HCV in people prescribed OST?

**Qualitative study**

7. Is the pharmacist-led pathway an acceptable way to offer testing and treatment for people prescribed OST infected with HCV and are there any unexpected consequences?

**METHODS**

**Design**

Super directly observed therapy (DOT)-C is a cluster randomised trial of pharmacy-led anti HCV therapy
Eligibility criteria

Eligible pharmacies are community based, offer DBST for HCV by trained pharmacy staff in line with approved practice in their particular NHS board and have at least 30 patients on OST to ensure adequate recruitment. Patient inclusion criteria are having HCV PCR positive to genotype 1 or 3, OST users and willing to have their pharmacists supervise their antiviral drug use. Patient exclusion criteria are having another genotype than 1 or 3, evidence of current or previous decompensated liver disease, HIV infection, surface antigen of hepatitis B virus (HBV) positive with detectable HBV DNA, aggressive or violent behaviour towards the pharmacist, being pregnant and not being able to provide informed consent.

Interventions

Medication provided

The anti-HCV treatment provided in both pathways is identical:

- For HCV genotype one sofosbuvir/ledipasvir for 8 weeks

- For HCV genotype three sofosbuvir/daclatasvir for 12 weeks

Study site staff training

Staff from each study site will receive training on Good Clinical Practice (GCP), quality control, use of study documentation, ensuring common practice and consenting participants. In addition training to establish testing for bloodborne viruses is provided and information on hepatitis C and its treatment is provided. Staff in the pharmacy-led arm are trained on how to interpret laboratory bloods and to perform a Fib4 calculation.

Conventional care pathway

At the start of the pathway pharmacists will opportunistically discuss HCV infection with their OST patients. The pharmacist will record on a screening log which of the OST patients attending the pharmacy they have approached. Those with unknown HCV status will be offered testing using DBST in the pharmacy. Patients identified as having HCV antibodies will have a post-test discussion with the pharmacist. During this discussion the pharmacists will obtain informed consent and explain about HCV infection with its treatment provided. Staff in the pharmacy-led arm are trained on how to interpret laboratory bloods and to perform a Fib4 calculation.

| Table 1 | Treatment pathways: similarities and differences |
|---------|---------------------------------------------|
| Conventional care | Pharmacy pathway | Contrast |
| HCV testing | Opportunistic HCV testing on presentation for OST therapy | Opportunistic HCV testing on presentation for OST therapy | The same procedure is provided in each of the study arms |
| HCV test confirmation | Test result is communicated and—if positive—referred for assessment in local treatment centre | Test result is communicated and—if positive—assessment directly undertaken in the pharmacy | Assessment for treatment is carried out at the pharmacy when the participant visits to obtain OST, not at a different site with a different provider |
| Treatment initiation | Suitable patients are prescribed treatment by a pharmacist prescriber at the local treatment centre and access treatment through DOT at their pharmacy | Suitable patients are prescribed treatment by a pharmacist prescriber and access treatment through DOT at their pharmacy | Treatment initiation is carried out at the pharmacy and not at a different site with a different provider |
| Treatment monitoring | Treatment monitoring is carried out by the specialist team in their clinic | Treatment monitoring is carried out at the pharmacy | Treatment monitoring is carried out at the pharmacy, not at a different site. Monitoring in the conventional pathway requires additional clinic visits |
| Treatment completion | SVR testing is carried out by DBST at the pharmacy | SVR testing is carried out by DBST at the pharmacy | The same procedure is provided in each of the study arms |

DBST, dried blood spot testing; DOT, directly observed therapy; HCV, hepatitis C virus; OST, opioid substitution therapy; SVR, sustained virological response. 

versus conventional care in patients with HCV infection attending community pharmacies (table 1). Sixty pharmacies will be enrolled in this study across five hubs in health boards in National Health Service (NHS) Scotland. Pharmacies (and thus their patients) participating in the trial will be randomly allocated to conventional care pathway or the pharmacy-led pathway.

Pharmacies at each site are randomised into two groups: conventional care and pharmacist-led care. Randomisation will be carried out using http://www.randomization.com. The subjects are randomised into one block along with the number of subjects per block/number of blocks and (case-sensitive) treatment labels. The pharmacies in each hub provide the level of randomisation, so patient allocation is dependent on the pharmacy attended.
markers of liver fibrosis (Fib4, APRI, AST:ALT ratio) and viral parameters (genotype and load), as assessment for treatment. Patients who are referred for assessment and treatment will be managed according to the standard local treatment pathway. Daily supervised OST treatment is delivered by the pharmacy, in which the doses of methadone or buprenorphine are provided by the pharmacy staff, who observe consumption. In both arms of the study DAA treatment is delivered jointly with OST in their normal pharmacy; which would qualify as DOT during weekdays, although at weekends patients usually self-administer. Prescriptions will be provided by a nurse prescriber and dispensed at the participant’s normal pharmacy. For doses that patients have to self-administer and the weekend doses when there is no OST distribution, the pharmacist and patient will make a brief if-then action plan (an implementation intention) and coping plan (to overcome anticipated barriers). The study-related data collection will be undertaken by the specialist hepatitis team.

Pharmacist-led pathway

Potential participants are offered testing, recruited and consented as in the conventional pathway. In the pharmacy-led pathway however, the pharmacist will offer them anti-HCV therapy delivered solely within the pharmacy. The patients who decline study participation will be entered in the screening log. For the patients who do consent, the pharmacist will complete a pretreatment checklist of medical comorbidities, medical history and concomitant medication to look for drug-drug interactions. The patient will undergo phlebotomy in the pharmacy for safety blood tests, as in the conventional pathway and the pharmacist will assess this information to determine suitability for treatment.

If there are no contraindications to therapy, the patient will commence the treatment. In patients where there are contraindications or queries about suitability, the pharmacist will contact the central clinical coordinator for advice. The pharmacist-led pathway requires an assessment which includes identification of concurrent specific medical conditions, screening of safety bloods, calculation of a Fib-4 score, assessment of interacting concurrent medication and assessment of factors likely to impinge on treatment compliance. Potential participants with a Fib-4 score of >3.25 are referred on to the conventional care pathway for review. The pharmacist-led pathway therefore excludes this group from being entered into the trial. Instead, they are assessed for treatment through the conventional care pathway where they are reviewed in hospital by a medical consultant who decides if it is safe to proceed with treatment and, if yes, may select different drugs. Unsuitable patients are therefore referred to the conventional pathway for assessment outside the study and provided with standard clinical care. Prescriptions for treatment will be provided by a pharmacist prescriber.

Each time that patients pick up their medication from the pharmacy a daily log is completed recording any occurrence of side effects or adverse events (AEs).

Participants who do not attend the pharmacy for seven consecutive days will be discontinued from the study since they will be deemed to have discontinued their course of DAA treatment and will have had their OST prescription suspended.

Participants are likely to be retained within the study through the mechanism of daily attendance for receipt of supervised OST; this is a powerful mechanism making people return to the pharmacy. It is intended that data will still be collected on participants who may not complete their course of treatment, since partial completion may produce an SVR also.

The primary study outcome (SVR 12 weeks after treatment completion) is assessed by DBST in the pharmacies for both study arms.

Outcomes and measures

The denominator for the outcomes on treatment uptake is the number of people using OST at the pharmacies participating in the respective arms. For the primary outcome, the numerator will be the number of patients with SVR at 12 weeks post-treatment completion (SVR12) after allocation to treatment arm, measured through a test for the presence of HCV RNA (PCR).

For the secondary outcomes on treatment uptake, the denominators are the number of patients who (1) Undergo HCV testing. (2) Initiate HCV treatment. (3) Complete the 12-week HCV course. (4) Number of patients with SVR at 12 months (to assess the impact of potential re-infection).

Study schedule

For both arms, screening for HCV by DBST is undertaken prior to recruitment (t0); participant consent (t1) is followed by 8 weeks or 12 weeks of treatment according to HCV genotype (t12), 12 weeks post-treatment a final SVR test is taken to determine the study outcome (tm,point).

Sample size

Approximately 22,000 patients are prescribed OST across Scotland. Around 85% of these patients receive daily or regular supervision of their OST consumption through one of the 1200 community pharmacies. It is expected that at least 40% of these patients will be infected with HCV, and that around 46% and 48% of infections will be with genotype 1 and genotype 3, respectively. The pharmacies acting as cluster sites for this trial have around 1800 patients attending for supervised OST administration. Sixty community pharmacies based around five study sites within Scottish NHS boards, will be coordinated through the Tayside Clinical Trials Unit (TCTU) of the Tayside Medical Science Centre, University of Dundee.

As the pharmacy-led pathway is a specific population-based intervention, the number of patients on OST treatment at each pharmacy will be the denominator.
for calculating DBST uptake. HCV infection status of all the OST patients in the denominator population is not known. National data repeatedly show approximately 40% of patients on OST are HCV-positive. As this is a randomised trial, it can be assumed that the rate of HCV positivity in the OST patients/pharmacies randomised to the pathways should be the same. The study will be powered through rates of HCV therapy offered. Approximately 3% of HCV-positive OST patients enter HCV therapy per year via conventional pathways, with 2.5% of the total eligible population achieving SVR per annum. If it is expected that the new pathway increased this to 15%, a sample in each arm of 141 (2N=282) will give 90% power at the significance level. The clustered design requires inflation to account for intraclass correlation, so if the average infected subjects per pharmacy is 12, the inflation factor for sizes of cluster, assuming an intraclass correlation of 0.05, is 1.55. This leads to a need for 2n=437.

The sample of 60 pharmacies with an average of 30 OST patients per pharmacy gives 1800 OST patients; assuming 40% are HCV-positive gives 700 to 800 potential patients for the study. This gives significant protection against any changes in baseline SVR success rates, and against pharmacy dropouts or local issues that prevent an enrolled pharmacy from participation. This is a trial of a pathway so all eligible patients are the denominator for the power calculation, not the patients who actually enter the pathway and are treated.

The randomisation of the pharmacies will be stratified by the associated hub centre. As the end point of the study is the effectiveness of the pathway, any dropouts are part of the study outcomes, so there is no need to increase the sample size to allow for a dropout rate.

Data collection, management and analysis

Analysis of the trial will follow the principles outlined in the ICH E9 ‘Statistical Principles for Clinical Trials’ and carried out by the UK Clinical Research Collaboration (UKCRC) registered Tayside TCTU. Prior to data lock an agreed statistical analysis plan will be finalised covering the prespecified statistical analysis.

The primary outcome of SVR will be assessed as a binary outcome for subjects and so will use logistic regression modelling. The numerator will be the number of subjects achieving SVR at 12 weeks and the denominator will be total number of patients using OST and having an HCV infection diagnosed at the participating pharmacies. Additionally results will be expressed as a proportion of the estimated HCV-infected subjects on OST. The estimated number of infected patients will be based on national survey data and the empirical rate discovered in the trial (allowing for patients who refuse testing). In order to account for the clustered nature of the trial, a mixed-effects logistic regression model will be used with the parameter indicator of the trial arm in the model and a random parameter to account for within-cluster correlation as well as stratified by hub. As all patients will have either achieved SVR or not, and we will assume that dropouts/lost to follow-up are failures, there will be no missing data in the primary outcome. Extrabinominal variability or overdispersion will be examined in the logistic model and, if present, alternative modelling such as negative binomial models will be considered. This will also be adjusted by therapy and genotype; the two factors are interdependent determining length of therapy.

Secondary binary outcomes will be analysed by the same procedure, initially as intention to treat with all eligible patients as the denominator and then exploring the steps in the pathway by per protocol analysis in particular to analyse treatment success:

- Proportion of HCV tested: within the duration of the study of those attending pharmacy sites for OST, for the conventional and for the pharmacist-led arms.
- Proportion that initiate HCV treatment within the duration of the study of those identified with HCV, for the conventional and for the pharmacist-led arms.

Proportion of those initiating treatment that complete the course: Multiple logistic regression modelling will explore the patient and pharmacy characteristics that are associated with the secondary and primary outcomes. Patient outcomes considered will be:

- Age.
- Gender.
- Deprivation.
- Employment.
- Comorbidity.
- Psychosocial variables assessed.

Pharmacy characteristics considered will be:

- Geographical location.
- Type of pharmacy service.
- Size of OST population.

Determination of re-infection: As the determination of possible re-infection is an important and stated secondary outcome in this study, all patients will be invited to consent for a further DBS HCV PCR 1 year after end of therapy or at end of the study, whichever is first. Those patients who achieve SVR will be invited to participate at their pharmacy. People prescribed OST are retained in the service for many years, since their progress of recovery and becoming drug-free is slow. In addition, movement out of Dundee, which is relatively geographically isolated, is minimal. We are therefore confident that we can identify all patients still in receipt of a prescription for OST and invite them to be re-tested for hepatitis C. Since the network of pharmacies providing OST is also trained to provide testing, we believe this is feasible.

Data management

An Excel database will be used to hold the study-related data. This will be managed and controlled by the coordinating pharmacist in NHS Tayside with site-specific data being transcribed from a paper case report form (CRF) formulated in line with the Excel database, with the study protocol and in line with the requirements of the investigators. Development and validation of the study
database, quality control and extraction of data will be done according to study sponsor procedures. Extracts for analysis will be based on the data tables provided by the study team.

**Health economic assessment**

Economic analysis will be undertaken alongside the trial, using the costs, resource use and effectiveness data generated within the trial. The number of SVRs achieved at the end of the trial will be combined with the cost data to calculate the incremental cost per cure. A longer-term analysis incorporating the cost and benefits of potential lifetime gains through citizenship will be undertaken.

**Qualitative assessment**

The qualitative research will take the form of a process evaluation building on previous exploratory and preparatory work. It will contribute to the assessment of the feasibility and acceptability to service users and providers of a pharmacy-led testing and treatment pathway (including identification of barriers and facilitators and unintended consequences of participation).

Interviews will be conducted with small samples of (1) Consenting study participants. (2) Professionals providing the pharmacist-led pathway by researchers at University of Dundee.

Qualitative interviews will be conducted with consenting participants and professionals using semistructured topic guides developed in line with the research aims. Topics will not be explored in a prescriptive manner but as part of an open discussion. This flexible format will enable additional salient topics and insights to emerge. In broad terms, the focus for the different respondent groups will be as follows:

One-to-one interviews with consenting participants (all of whom have engaged with the service) will explore views on issues around the delivery and promotion of the pharmacist-led pathway, their response to the offer and delivery of treatment, and any unintended consequences.

Interviews with professionals will explore issues around implementation of the intervention and the trial elements, identify challenges and ways they have been overcome, and perceived response among participants.

With the interviewee’s consent, all interviews and focus group discussions will be recorded as digital audio files, which will then be transcribed in full for thematic analysis. Transcripts will be organised using a thematic framework based on topics specified in the topic guide and emerging themes identified through a process of familiarisation with transcript texts.

**Patient and public involvement**

In developing the research question and outcome measures for study, pilot work was undertaken using focus groups of people prescribed OST and their carers to explore their experiences of using community pharmacies. The priorities and experiences of people prescribed OST were further evaluated through a discrete choice experiment, which was used to aid the design of the pharmacy-led pathway. A process evaluation was employed as part of the development of the DBST intervention in pharmacies, where recipients were asked about their experiences and preferences for testing for hepatitis C. The process evaluation approach was also repeated as part of a feasibility study in which the assessment and treatment of hepatitis C in this group was piloted, to further understand how the intervention would be accommodated by participants. The information gained from this exercise has been fed back to groups of service users attending the local community support and harm reduction centre. Patients have not been involved in the recruitment to this study.

**DISCUSSION**

Liver disease has become a major cause of premature death in the developed world and HCV is a major contributor to this burden. The care of people infected with HCV therapy has undergone a paradigm shift due to the efficacy of DAA drugs and the consequent simplification of therapy, with highly effective treatment choices marketed across the world. However, new and more effective pathways of care are urgently required in order to enhance testing and linkage to care and treatment. These novel pathways of care need to be carefully evaluated both for efficacy and cost-effectiveness compared with traditional pathways, as well as for unintended consequences. This pragmatic, cluster-randomised trial can provide strong evidence of the effectiveness of a pharmacist-delivered care pathway for HCV eradication therapy in patients receiving OST. A comparison will be undertaken with the current clinical care pathway where patients are referred to a conventional clinic to receive their HCV treatment. Trial design has aimed for high applicability in design decisions and this trial is expected to directly inform the future organisation of care.

**Harms**

Regular follow-up of the participants will occur daily in the DOT arm during the study treatment period by a pharmacist familiar in the trial methodology. For those participants allocated to the conventional therapy, regular clinical follow-up will occur in line with prevailing conventional NHS standard of care. At each visit participants will be monitored for expected AEs as per the Summary of Product Characteristics for the drug treatments used in this study. This is in line with the current standard of care for the NHS and only AEs outside these criteria will formally be recorded as AEs.

Bloods for viral load would be performed as outlined in the study schedule, at the pre treatment visit and at 12 weeks postcompletion of therapy, as per the attached study schedule. Data on testing, referral, initiation of (and adherence to) therapy are routinely collected for the HCV clinical database and these data will also be used.
In addition baseline and end of treatment checking of prescribed and non-prescribed medications and drug use, as documented in the study concomitant medications log, will be carried out to investigate the relationship between any AEs and drug interactions.

**Consenting participants**

Potential participants will be approached by pharmacy staff familiar with the trial methodology and trained in GCP. They will be provided with information on the study verbally and via the patient information sheet and be given at least 24 hours to consider participation.

At their return visit for screening they will be interviewed by the study pharmacist and asked to sign an informed consent form, once they are satisfied that they have had adequate explanation from the pharmacist explaining the trial to them.

**Confidentiality**

The data will be collected by the researcher (treatment delivering pharmacist or nurse) on a paper CRF with subsequent transcription to electronic CRF. Electronic storage will be in an encrypted form on a password-protected device. The medical notes will act as source data for past medical history and blood results.

All laboratory specimens, evaluation forms, reports and other records will be identified in a manner designed to maintain participant confidentiality. All records will be kept in a secure storage area with limited access to study staff only. Clinical information will not be released without the written permission of the participant, except as necessary for monitoring and auditing by the Sponsor or its designee. The chief investigator and study staff involved with this study will not disclose or use for any purpose other than performance of the study, any data, record, or other unpublished, confidential information disclosed to those individuals for the purpose of the study. Prior written agreement from the sponsor or its designee will be obtained for the disclosure of any said confidential information to other parties.

**Data protection**

The chief investigator and study staff involved with this study will comply with the requirements of the Data Protection Act 1998 with regard to the collection, storage, processing and disclosure of personal information and will uphold the Act’s core principles. The chief investigator and study staff will also adhere, if appropriate, to the current version of the NHS Scotland Code of Practice on Protecting Patient Confidentiality. Access to collated participant data will be restricted to the chief investigator and appropriate study staff. Computers used to collate the data will have limited access measures via usernames and passwords. Published results will not contain any personal data that could allow identification of individual participants.

**Trial organisation**

**Trial management**

Overall management of the trial is being provided by TCTU, a UKCRC-registered clinical trials unit. A study clinical trial manager supported by a study coordinator will oversee the study and will be accountable to the chief investigator. They will be responsible for checking CRFs for completeness, plausibility and consistency. However, this remains the overall responsibility of the chief investigator. Any queries will be resolved by the chief investigator or a delegated member of the study team.

A study-specific delegation log will be prepared for the study at each site, detailing the responsibilities of each member of staff working on the study.

A trial steering committee will be established to oversee the conduct and progress of the study. The steering committee will include the investigators above, as well as the NHS Tayside Director of Pharmacy and a representative from the Chief Pharmaceutical Officer’s team of the Scottish Government. The steering committee will take all executive decisions. The responsibility of the steering committee is to ensure the scientific integrity and quality of the project. To achieve this, the specific responsibilities of the steering committee include: maintaining adherence to the study protocol; approving changes to study protocol if required; reviewing quality assurance indicators; monitoring study recruitment and the overall study timetable; advising, as required, on specific scientific items that may arise; compliance with legislation; adherence to research governance; reporting to funders; approving publication and dissemination strategies. The steering committee will meet every 6 months.

**Trial status**

Recruitments commenced in December 2016. On 9 October 2017, 234 were consented to the trial.

**Reporting guideline**

SPIRIT 2013 statement: defining standard protocol items for clinical trials http://annals.org/aim/article/1556168/spirit-2013-statement-defining-standard-protocol-items-clinical-trials.

**Author affiliations**

1Directorate of Public Health, NHS Tayside, Kings Cross Hospital, Dundee, UK
2Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
3Tayside Clinical Trials Unit, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
4Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK

**Collaborators**

Stephen Thomas Barclay, Andrew Fraser.

**Contributors**

AR: study conception, planning and design, protocol preparation, manuscript preparation. MdB: conception, planning and design, protocol preparation, manuscript preparation. JFD: study conception and design, protocol preparation, manuscript preparation. SKI: protocol preparation, planning and design, randomisation, study management, manuscript preparation. PTD: study conception, planning and design, statistical advice, protocol preparation, manuscript preparation.

**Funding**

This study was funded in partnership by the Scottish Government, Gilead and Bristol-Myers Squib. The funders have no responsibilities for or authority over study design; collection, management, analysis or interpretation of data; writing of the report; and the decision to submit the report for publication.

**Competing interests**

AR: honorariums from Gilead and Abbvie; Research Grants from Gilead and Roche. JFD: research grants and honorariums from Abbvie, Bristol
Myers Squibb, Gilead, Janssen, Merck Roche Sharp & Dohme and Roche. PTD: research grants from Novo Nordisk, GSK, Shire Pharmaceuticals, Gilead and Bristol Myers Squibb; member of the New Drugs Committee of the Scottish Medicines Consortium. SKI and MdB: none.

**Patient consent** Not required.

**Ethics approval** Approval was received for this study (15/ES/0086) from East of Scotland Research Ethics Committee 2 on 27 May 2016.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**REFERENCES**

1. Scottish Intercollegiate Guidelines Network (SIGN). Management of hepatitis C. Edinburgh: SIGN; 2013. (SIGN publication no. 133). 2013 http://www.sign.ac.uk (accessed Sep 2018).

2. Arain A, Robaey G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. *World J Gastroenterol* 2014;20:12722–33.

3. Public Health England. Hepatitis C annual report: progress made, but much more to do. 2014 https://www.gov.uk/government/news/hepatitis-c-annual-report-progress-made-but-much-more-to-do (accessed Sep 2018).

4. Martin NK, Foster GR, Vilar J, et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. *J Viral Hepat* 2015;22.

5. Aspinall EJ, Doyle JS, Corson S, et al. Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis. *Eur J Epidemiol* 2015;30:115–29.

6. Grebely J, Bruneau J, Bruggmann P, et al. Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. *Int J Drug Policy* 2017;47:263–33.

7. Tait JM, Wang H, Stephens BP, et al. Multidisciplinary managed care networks: Life-saving interventions for hepatitis C patients. *J Viral Hepat* 2017;24.

8. McAllister G, Innes H, Mcleod A, et al. Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland. *J Clin Virol* 2014;61:359–64.

9. European Monitoring Centre for Drugs and Drug Addiction. Hepatitis C among drug users in Europe: epidemiology, treatment and prevention, EMCDATA Insights 23. Luxembourg: Publications Office of the European Union, 2016.

10. Treloar C, Newland J, Rance J, et al. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. *J Viral Hepat* 2010;17:839–44.

11. Lavanchy D. The global burden of hepatitis C. *Liver Int* 2009;29 Suppl 1:74–81.

12. Konerman MA, Lok AS. Hepatitis C treatment and barriers to eradication. *Clin Transl Gastroenterol* 2016;7:e193.

13. Radathy a, van der Poel M, Dillon JF. Designing a hepatitis C testing service in primary care: a discrete choice experiment. *Gut* 2016;64(S1) http://gut.bmj.com/content/64/Suppl_1/A103.2.

14. Radley A, Melville K, Tait J, et al. A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland. *Frontline Gastroenterol* 2017;8:221–8.

15. Radley A, Tait J, Dillon JF. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy. *Int J Drug Policy* 2017;47:126–36.

16. Loudon K, Treweek S, Sullivan F, et al. The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ* 2015;350:h2147.

17. Sterling RK, Lissen E, Clumcke N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006;43:1317–25.

18. Tait JM, Stephens BP, McIntyre PG, et al. Dry blood spot testing for hepatitis C in people who injected drugs: reaching the populations other tests cannot reach. *Frontline Gastroenterol* 2013;4:255–62.

19. Gollwitzer PM, Sheeran P. Implementation intentions and goal achievement: a meta-analysis of effects and processes. *Advances in Experimental Social Psychology* 2006;38:89–119.

20. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol* 2017;2:161–76.

21. He T, Lopez-Obilo MA, Hur C, et al. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2–6. *Aliment Pharmacol Ther* 2017;46:711–21.